Celyad Oncology SA (CYAD.BR)
Brussels · EUR · Healthcare · Biotechnology
€0.21 (+1.45%) as of
Key statistics
- Market cap
- 15.73M
- P/E (TTM)
- 2.62
- Forward P/E
- 0.33
- EPS (TTM)
- 0.0800
- Dividend yield
- 0.00%
- 52-week range
- 0.1600 – 0.6500
- Beta
- 1.25
- Revenue (TTM)
- 7k
- Profit margin
- 47,071.43%
- Volume
- 11.78k
About Celyad Oncology SA
Celyad Oncology SA, a biotechnology company, focuses on unlocking the potential of its intellectual property. Its portfolio comprises multiple foundational US patents focused on TCR-deficient T cell compositions, and it broadly covers allogeneic CAR T cell therapies. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Mont-Saint-Guibert, Belgium
- Employees
- 4
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.